Trial · NCT03088930
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
NCT03088930, Phase 2, Completed, University of Colorado, Denver; results first posted 2022-02-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer. Trials, record NCT03088930. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03088930
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
- NCT number
- NCT03088930
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Lung Cancer, Nonsmall Cell
- Interventions
- Crizotinib
- First posted
- 2017-03-23
- Last updated
- 2022-02-11
- Results first posted
- 2022-02-11
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Number of Participants With an Objective Tumor Response Rate | 6 weeks | Participants' tumor response to treatment will be compared from initial/pretreatment scan to 6 week scan using RECIST 1.1 |
| Secondary | The Number of Participants With Pathologic Response Rate | 37 months | Pathologic response rate is defined as \< 50% of viable tumor present histologically in the resected tumor specimen. |
| Secondary | Number of Participants With an Objective Response Rate | 6 weeks post treatment | Number of participants with response rate per RECIST 1.1 |
| Secondary | The Number of Participants With Disease-free Survival (DFS) | 37 months | DFS is defined as the time from treatment to the first of either disease recurrence or death from any cause. |
| Secondary | Overall Survival (OS) Measured in Months | 37 months | OS is defined as the time from study enrollment to death from any cause. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Number of Participants With an Objective Tumor Response Rate | 6 weeks | participants | NUMBER | |
| SECONDARY | The Number of Participants With Pathologic Response Rate | 37 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With an Objective Response Rate | 6 weeks post treatment | participants | NUMBER | |
| SECONDARY | The Number of Participants With Disease-free Survival (DFS) | 37 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Survival (OS) Measured in Months | 37 months | months | MEDIAN |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Participants With an Objective Tumor Response Rate | Neoadjuvant Treatment With Crizotinib | 3 | participants | ||
| The Number of Participants With Pathologic Response Rate | Neoadjuvant Treatment With Crizotinib | 0 | Participants | ||
| Number of Participants With an Objective Response Rate | Neoadjuvant Treatment With Crizotinib | 0 | participants | ||
| The Number of Participants With Disease-free Survival (DFS) | Neoadjuvant Treatment With Crizotinib | 0 | Participants | ||
| Overall Survival (OS) Measured in Months | Neoadjuvant Treatment With Crizotinib | 37 | Full Range 0 to 37 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Neoadjuvant Treatment With Crizotinib | 3 | |
| Overall Study | COMPLETED | Neoadjuvant Treatment With Crizotinib | 3 | |
| Overall Study | NOT COMPLETED | Neoadjuvant Treatment With Crizotinib | 0 |
Source ClinicalTrials.gov
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Neoadjuvant Treatment With Crizotinib | 1 | 3 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Neoadjuvant Treatment With Crizotinib | 2 | 3 | 2 |
| other | Insomnia | General disorders | Neoadjuvant Treatment With Crizotinib | 1 | 3 | 1 |
| other | Influenza | Respiratory, thoracic and mediastinal disorders | Neoadjuvant Treatment With Crizotinib | 1 | 3 | 1 |
| other | creatinine increased | Blood and lymphatic system disorders | Neoadjuvant Treatment With Crizotinib | 1 | 3 | 1 |
| other | cough | Respiratory, thoracic and mediastinal disorders | Neoadjuvant Treatment With Crizotinib | 1 | 3 | 1 |
| other | blurred vision | Eye disorders | Neoadjuvant Treatment With Crizotinib | 2 | 3 | 2 |
| other | headache | General disorders | Neoadjuvant Treatment With Crizotinib | 1 | 3 | 1 |
| other | epigastric discomfort | Gastrointestinal disorders | Neoadjuvant Treatment With Crizotinib | 1 | 3 | 1 |
| other | bradycardia | Cardiac disorders | Neoadjuvant Treatment With Crizotinib | 1 | 3 | 1 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Neoadjuvant Treatment With Crizotinib | 1 | 3 |
| Total, other adverse events | Neoadjuvant Treatment With Crizotinib | 3 | 3 |
| Total, serious adverse events | Neoadjuvant Treatment With Crizotinib | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03088930
GET https://conductscience.org/api/trials/v1/NCT03088930/registered